Senti Biosciences, Inc. - Common Stock SNTI 深 沪
等待开盘 07-21 09:30:00 美东时间
1.95
-0.060
-2.99%
华盛通- 最 高2.08
- 今 开2.08
- 成交量 16.97万股
- 最 低 1.9306
- 昨 收 2.01
- 总市值 5085.81万
- 52周最高 16.94
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.5201
- 委 比 11.50%
- 总股本 2608.11万
- 历史最高 87.70
- 量 比 0.11
- 振 幅 7.43%
- 历史最低 1.77
- 每 手 1
- 风险率 1.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Senti Biosciences Appoints Bryan Baum to Board
The latest update is out from Senti Biosciences ( ($SNTI) ). On July 18, 2025, ...
07-18 21:17
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
Senti Biosciences appoints Bryan Baum to its Board of Directors. Baum is a successful entrepreneur and investor, co-founding K5 Global and investing in notable companies like SpaceX and OpenAI. He brings expertise in scaling innovative ventures, which Senti Bio aims to leverage to advance its Gene Circuit platform for cell and gene therapies. Baum expressed excitement about Senti's potential to revolutionize cancer treatments through logic-gated ...
07-18 12:55
Senti Biosciences Holds 2025 Annual Stockholders Meeting
Senti Biosciences ( ($SNTI) ) has shared an update. On June 25, 2025, Senti Bio...
07-01 04:43
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
Senti Biosciences, Inc. will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference in Houston, TX, June 23-26. The presentation, titled "Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells," will be led by CEO Timothy Lu, MD, PhD, on June 24 at 1:20 PM CT. The SEED Conference is a leading event for synthetic biologists to share advancements and network. Senti Bio, leveraging its Gene ...
06-24 12:45
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
Senti Biosciences announced that the FDA has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory acute myeloid leukemia (AML). SENTI-202, a first-in-class off-the-shelf CAR NK cell therapy, targets CD33 and FLT3-expressing hematologic malignancies while sparing healthy cells. With 20,800 new AML cases in the U.S. annually and a dismal median survival rate, the designation underscores the need for innovative treat...
06-18 11:00
Senti Biosciences gets FDA Orphan Drug Designation For SENTI-202 For Treatment Of Acute Myeloid Leukemia
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1078725
06-17 23:51
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
Senti Biosciences Announces New Employment Inducement Grants
Senti Bio, a biotechnology company, recently awarded stock options to eight new employees, granting them the right to purchase 102,500 shares at $3.03 per share under its 2022 equity plan. The company focuses on developing cell and gene therapies for incurable diseases using its Gene Circuit platform, targeting challenging tumor indications.
06-09 20:30
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
Laidlaw & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $15
Laidlaw & Co. analyst Yale Jen initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Buy rating and announces Price Target of $15.
06-07 00:15
